|Mr. Thomas Andrew Butler||Co-Founder, Chairman & CEO||772.86k||N/A||1981|
|Mr. Ramses M. Erdtmann||Co-Founder, Pres, COO & Director||570.57k||N/A||1963|
|Mr. Franco Valle||CFO & Principal Accounting Officer||251.69k||N/A||1981|
|Mr. Heow Tan||Chief Technology & Quality Officer||N/A||N/A||1959|
|Van Sandwick||Director of Investor Relations & Corp. Devel.||N/A||N/A||N/A|
|Ms. Naomi Cretcher||Chief People Officer||N/A||N/A||N/A|
|Dr. Thorsten Kirschberg Ph.D.||Exec. VP of Chemistry||N/A||N/A||1970|
|Mr. Anthony Souza||Director & Head of Information Technology||N/A||N/A||N/A|
|Dr. Stephan Morris M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Ms. Terrie Phan||VP & Corp. Controller||N/A||N/A||N/A|
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Biomea Fusion, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.